| Not Yet Recruiting | "Observational, Retrospective and Prospective, Non-interventional, Multicentre on the Use of Genomic Testing i Breast Cancer | — | 2025-03-01 |
| Recruiting | Measure of Outcomes in Patients With Advanced Ovarian Cancer According to Homologous Recombination Status and Ovarian Cancer | — | 2024-09-13 |
| Recruiting | Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients Metastatic Renal Cell Carcinoma | Phase 2 | 2023-04-18 |
| Unknown | Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer Oligometastatic Renal Cell Carcinoma | Phase 2 | 2023-03-14 |
| Unknown | Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cance Breast Cancer | — | 2021-07-27 |
| Unknown | Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma Renal Carcinoma Metastatic | Phase 2 | 2020-10-07 |
| Unknown | Atezolizumab Plus CArboplatin Plus Nab-paclitaxel Metastatic Breast Cancer, Triple Negative Breast Cancer, PD-L1 Gene Mutation | Phase 2 | 2020-07-03 |
| Active Not Recruiting | Prospective Observational Study of Adjuvant Hormone Treatment in Estrogen-receptor Positive Premenopausal Earl Early Breast Cancer | — | 2019-10-24 |
| Unknown | Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Recepto Metastatic Breast Cancer, Locally Advanced Breast Cancer | Phase 2 | 2019-07-16 |
| Completed | Avelumab as Single Agent in Metastatic or Locally Advanced Urothelial Cancer in Patients Unfit for Cisplatin. Metastatic or Locally Advanced PD-L1 Positive Urothelial Cancer | Phase 2 | 2019-02-06 |
| Completed | Liquid Biopsy: Intercepting Mutational Trajectories of HER2 (Human Epidermal Growth Factor Receptor 2) Breast Metastatic Breast Cancer | N/A | 2018-11-07 |
| Unknown | Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cance Metastatic Breast Cancer | Phase 2 | 2018-07-30 |
| Unknown | CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progre Prostate Cancer, Castration-resistant Prostate Cancer | Phase 2 | 2017-11-22 |
| Unknown | Dexamethasone-sparing Approach Including NEPA Against Emesis Caused by Cisplatin Chemotherapy-induced Nausea and Vomiting | Phase 3 | 2016-11-25 |
| Unknown | Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Renal Cell Carcinoma, Kidney Cancer | Phase 1 / Phase 2 | 2016-11-01 |
| Completed | NEPA to Prevent Chemotherapy Induced Nausea and Vomiting in Patients With Breast Cancer Chemotherapy-induced Nausea and Vomiting | Phase 2 | 2016-05-12 |
| Unknown | Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer Metastatic Breast Cancer, Breast Cancer, Hormone Receptor Positive Tumor | Phase 3 | 2015-12-01 |
| Unknown | Evaluation of Medical Treatments in MBC Patients According Biological Subtype and Line of Treatments Metastatic Breast Cancer | — | 2015-11-01 |
| Unknown | Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 - Postmenopausal MBC Patients Metastatic Breast Cancer | Phase 3 | 2015-11-01 |
| Unknown | Observation of Medical Treatments in MBC HER2-negative Patients Metastatic Breast Cancer | — | 2015-05-01 |
| Unknown | Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER Metastatic Breast Cancer | Phase 2 | 2014-11-01 |
| Unknown | Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Pati Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Phase 2 | 2014-09-01 |
| Completed | FEC With G-CSF Support Followed by Ixabepilone With G-CSF Support as Neoadjuvant Chemotherapy in BC Breast Cancer | Phase 2 | 2008-09-01 |
| Unknown | Overcoming Endocrine Resistance in Metastatic Breast Cancer Metastatic Breast Cancer | Phase 3 | 2007-11-01 |